Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)

NCT04651439 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04651439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04651439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2/3
Overall status
Unknown status
Start date
May 13, 2022
Completion date
May 13, 2026
Enrollment
42 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rare diseases, toxic epidermal necrolyses